Recruiting Phase 1 2025-523304-68-00

A research study to evaluate the safety of NNC1679-0001 when given to healthy participants and participants with T2DM

Phase 1 – testing safety in a small group of people

Conditions: Healthy participants and participants with type 2 diabetes

Sponsor: Novo Nordisk A/S

trial.available_in:

БГ

Overview

Trial status: Authorised

Who can participate

Age group: 18-64 years Gender: Female, Male Target enrollment: 80 participants

Austria (1)

Status

Recruiting

Phase

Phase 1

Study type

INTERVENTIONAL

Sex

Male and female

Minimum age

18 Years

Maximum age

64 Years

Healthy volunteers

Start date

19.04.2026

Registry ID

2025-523304-68-00

Source

euclinicaltrials.eu

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.